Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2025-01-01
|
| Collection: | Leukemia Research Reports |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S2213048925000317 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|